Avitar Invited to Present at Emerging Medical Technologies East Conference
Tomorrow in Cambridge

CANTON, Mass., Sep 5, 2001 /PRNewswire via COMTEX/ -- Avitar, Inc. (Amex: AVR)
today announced that it has been invited to make a presentation at IHS Health
Group's Emerging Medical Technologies East (EMT) Conference & Exhibition on
Thursday, Sept. 6, at 3:30 p.m. at the Hyatt Regency Hotel in Cambridge, MA.

Avitar will be one of approximately 40 companies presenting during the two-day
conference to an audience of investment professionals and industry leaders.
Following Avitar's presentation, the company will participate in a breakout
session for smaller group and one-on-one discussions. On Thursday evening,
there will be a reception/exhibition with a tabletop display of products and
literature.

This is the 5th annual Emerging Medical Technology Conference, and the eighth
year that EMT conferences have been held in both the U.S. and Europe, to enable
companies to potentially discuss areas such as financing, corporate alliances,
joint ventures and distribution agreements

"We look forward to presenting at the EMT East Conference this week, and to be
among the cutting-edge medical technology companies that will be in
attendance," said Peter P. Phildius, Avitar's Chairman and Chief Executive
Officer. "This conference is well-known for putting companies, as well as
investors, together to discuss areas of mutual interest."

ABOUT AVITAR

Avitar, Inc. (Amex: AVR) headquartered in Canton, Massachusetts, is a
diagnostics company that develops, manufactures and markets innovative and
proprietary medical devices in two major areas: the {*filter*}fluid {*filter*}-of-abuse
market and the disease & clinical testing market. {*filter*}fluid diagnostics
includes both the {*filter*}-of-abuse testing market estimated to be worth $1.5
billion encompassing the corporate workplace and criminal justice markets.
Avitar's products include ORALscreen(TM), the world's first non-invasive,
rapid, onsite {*filter*}fluid test for {*filter*}-of-abuse, and HAIRscreen(TM), a
laboratory-based hair test for detecting long-term drug abuse. In the $20
billion disease & clinical testing market, Avitar is currently developing
products that will address the conditions of Lyme disease, influenza and
diabetes, as well as pregnancy.

For more information, see Avitar's website at www.avitarinc.com.

This release contains forward looking statements that are subject to risks and
uncertainties including the development and marketing of new applications and
other risks that are detailed from time to time in the Company's filings with
the Securities and Exchange Commission.

{*filter*}fluid Lyme testing in the home>?!!!!!!!!
Sounds like a joke to me...
***********************************

DISEASE STATES IN DEVELOPMENT
Avitar has identified several growth opportunities in the in-vitro diagnostics
market that fit well with {*filter*}fluid POC tests. These applications include
glucose monitoring, Lyme disease, influenza, and pregnancy testing. Each of
these diagnostic segments was selected for their unique needs and the benefits
which {*filter*}fluid technology can provide; non-invasive collection, quick,
accurate and inexpensive.

Lyme Disease
Currently over 60% of the United States population is exposed to the dangers of
Lyme disease, a condition that induces arthritis-like symptoms in its victim.
Lyme disease is contracted most often via the bite of a deer tick, which is
prevalent in wooded areas in California and the Northeastern United States.
Recently, a vaccine for Lyme disease has been developed. However, often the
patient is unaware of the exposure risks to the disease until after they have
contracted it. Usually, results of the tests administered in the Physician's
office can take several days to be completed.

{*filter*}fluid testing in the home provides a unique opportunity for the rapid
diagnosis of Lyme disease and therefore faster treatment. Avitar recognizes the
advantages of {*filter*}fluid tests for the diagnostic market.